BioSpace News Archive

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company and a wholly owned and independently operated subsidiary of Bayer AG, announced that Philip Dana has been appointed to its executive team as Chief Human Resources Officer.

Calon Cardio-Technology Ltd. and Leviticus-Cardio Ltd. announce the joint Development and Testing of a Wireless, Fully Implantable, Long-Term Blood Pump.

PTC Therapeutics, Inc. will present an update on its commercial progress and R&D pipeline at the 40th Annual J.P. Morgan Healthcare Conference , Monday Jan. 10th at 7:30am EST. Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2021 accomplishments and highlight upcoming potential value-creating milestones.

HotSpot Therapeutics, Inc. and Caris Life Sciences® announced a strategic partnership to advance precision medicine approaches for HotSpot’s emerging product portfolio.

Skye Bioscience, Inc., a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued the following letter from Chief Executive Officer and Chair, Punit Dhillon.

Tiziana Life Sciences is pleased to announce that the U.S. Food and Drug Administration allowed enrollment of a second patient in the ongoing clinical treatment of secondary progressive multiple sclerosis with intranasally administered foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women’s Hospital, Harvard University, Boston, MA.

Medtronic plc, a global leader in healthcare technology, announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company.

BiondVax Pharmaceuticals Ltd. announced that it will present a company overview at the H.C. Wainwright Bioconnect Virtual Conference.

CVRx, Inc. announced certain preliminary unaudited fourth quarter and full year 2021 revenue results, and provided a 2022 business outlook.